Study summary
Immunotherapy let people skip cisplatin during radiation with no loss of benefit and far less vomiting
88.3%failure-free at 3 years without concurrent cisplatin, vs 87.6% with it
What was tested
Toripalimab plus induction chemotherapy and radiation, without the usual cisplatin during radiation, against standard treatment with cisplatin, for locally advanced nasopharyngeal carcinoma.
What they found
- 3-year failure-free survival was 88.3% without concurrent cisplatin vs 87.6% with it, meeting the non-inferiority test.
- Vomiting fell from 59.8% to 26.2%.
- Quality of life was better without cisplatin.
What it means
One of several trials showing immunotherapy can replace some of the harsher parts of standard treatment.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.